CN108938562A - Choline Glycerophosphate oral solution - Google Patents
Choline Glycerophosphate oral solution Download PDFInfo
- Publication number
- CN108938562A CN108938562A CN201710378798.7A CN201710378798A CN108938562A CN 108938562 A CN108938562 A CN 108938562A CN 201710378798 A CN201710378798 A CN 201710378798A CN 108938562 A CN108938562 A CN 108938562A
- Authority
- CN
- China
- Prior art keywords
- oral solution
- choline glycerophosphate
- choline
- glycerophosphate
- sweetener
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
Abstract
This disclosure relates to medicine field, specially Choline Glycerophosphate oral solution and its preparation process.The oral solution prescription is made of Choline Glycerophosphate, preservative, sweetener, essence and pure water, wherein the preferred aspartame of sweetener.Compared with Conventional solid preparation such as tablet, capsule, oral solution dispersion degree is big, absorbs fast, bioavilability height.Meanwhile the compliance of patient has can be improved in sweet phosphoric acid oral solution, and it is convenient that there is the patient for swallowing oral solid formulation difficulty to use, guarantee the accuracy of dosage.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to a kind of Choline Glycerophosphate oral solution.
Background technique
Choline Glycerophosphate is a kind of psychostimulant, can activate the central nervous system of elderly patients, wherein containing choline
With phosphocholine precursor.It can effectively act on the prevention and treatment for biochemical lesion.It can be clearly
The pathological factor of the various symptoms caused by organ collpase is identified, to reduce choline tensity and change the phosphatide of neural mucous membrane
Structure.Unlike other choline forms, Choline Glycerophosphate can be easier to enter blood-brain barrier under normal circumstances.Glyceryl
The chemical structure of Phosphorylcholine and relative chemico-physical properties complete normal metabolism for protection brain tissue
Provide sufficient nutriment.Pharmacological testing and the result of clinical research all confirm, for the mood caused by brain degeneration
When with abnormal behavior, glyceryl Phosphorylcholine has incomparable powerful intervention capacity to cognitive function and memory function.Face
Bed is for treating cerebral ischemia attack (apoplexy or transient ischemic attack) in 10 days, slightly to moderate Alzheimer,
And the patient of multi infarct dementia.It is the prescription medicine of liver protection good medicine and treatment senile dementia.
Compared with Conventional solid preparation such as tablet, capsule, oral solution dispersion degree is big, absorbs fast, bioavilability height.It is domestic
There are more document reports, medicine preparation is known as oral solution, bioavilability is higher than Conventional solid preparation.Open the research table such as jade
Bright: fluconazole bioavilability is better than fluconazole capsule.Liu Hanqing etc. is studies have shown that the equal biological utilisation of oral liquid of honeysuckle flower and scutellaria
Degree is substantially better than silver yellow tablet.Meanwhile the compliance of patient has can be improved in sweet phosphoric acid oral solution, it is convenient oral solid with swallowing
The patient of body preparation difficulty uses, and guarantees the accuracy of dosage.
Summary of the invention
This disclosure relates to medicine field, specially Choline Glycerophosphate oral solution.
The Choline Glycerophosphate oral solution, which is characterized in that containing Choline Glycerophosphate, preservative, sweetener, essence and
Pure water.
The Choline Glycerophosphate oral solution, which is characterized in that preservative is benzoic acid, sodium benzoate, methyl hydroxybenzoate, hydroxyl
Mixture more than one or both of phenethyl ester, Nipasol.
The Choline Glycerophosphate oral solution, which is characterized in that sweetener be D-sorbite, mannitol, fructose, sucrose,
Mixture more than one or both of maltose, lactose, glucose, xylitol, saccharin sodium, aspartame, stevioside, it is excellent
Select aspartame.
The Choline Glycerophosphate oral solution, which is characterized in that essence is apple, honey peach, cherry, orange taste, strawberry, is breathed out
Mixture more than one or both of close melon.
The Choline Glycerophosphate oral solution, which is characterized in that the ingredient comprising following ratio:
。
The preparation method of the Choline Glycerophosphate oral solution, comprising: the Choline Glycerophosphate for weighing recipe quantity pours into appropriate
In pure water, magnetic agitation sequentially adds preservative, essence, sweetener, magnetic agitation to whole dissolutions to its dissolution.
Specific embodiment
This disclosure relates to Racecadotril granules agent and its preparation process, those skilled in the art can be used for reference in this paper
Hold, is suitably modified realization of process parameters.In particular, it should be pointed out that all similar substitutions and modifications are to those skilled in the art
For be it will be apparent that they are considered as being included in the present invention.Method and application of the invention, which has passed through, preferably to be implemented
Example is described, related personnel obviously can not depart from the content of present invention, in spirit and scope to method described herein and
Using being modified or appropriate changes and combinations, carry out implementation and application the technology of the present invention.
Embodiment 1
。
Preparation process
The Choline Glycerophosphate for weighing recipe quantity, is poured into appropriate amount of purified water, magnetic agitation to its dissolution, sequentially add benzoic acid,
Flavoring apple essence, aspartame, magnetic agitation to whole dissolutions.
Embodiment 2
。
Preparation process
The Choline Glycerophosphate for weighing recipe quantity, is poured into appropriate amount of purified water, and magnetic agitation is sequentially added to its dissolution using boiling water
Ethyl hydroxy benzoate, saccharin sodium, the strawberry essence of dissolution, magnetic agitation to whole dissolutions.
Embodiment 3
。
Preparation process
The Choline Glycerophosphate for weighing recipe quantity, is poured into appropriate amount of purified water, and magnetic agitation is sequentially added to its dissolution using boiling water
Methyl hydroxybenzoate, peach flavor, the sucrose of dissolution, magnetic agitation to whole dissolutions.
Choline Glycerophosphate is prepared as oral solution, dispersion degree is big, absorbs fast, bioavilability height.Meanwhile sweet phosphoric acid is oral
The compliance of patient has can be improved in liquid, convenient that there is the patient for swallowing oral solid formulation difficulty to use, and guarantees dosage
Accuracy.
Claims (5)
1. a kind of Choline Glycerophosphate oral solution, which is characterized in that contain Choline Glycerophosphate, preservative, sweetener, essence and pure
Water.
2. Choline Glycerophosphate oral solution according to claim 1, which is characterized in that preservative be benzoic acid, sodium benzoate,
Mixture more than one or both of methyl hydroxybenzoate, ethyl hydroxy benzoate, Nipasol.
3. Choline Glycerophosphate oral solution according to claim 1 to 2, which is characterized in that sweetener is D-sorbite, sweet dew
One or both of alcohol, fructose, sucrose, maltose, lactose, glucose, xylitol, saccharin sodium, aspartame, stevioside with
On mixture, preferred aspartame.
4. Choline Glycerophosphate oral solution according to claim 1 to 3, which is characterized in that essence is apple, honey peach, cherry
Peach, orange taste, strawberry, mixture more than one or both of "Hami" melon.
5. Choline Glycerophosphate oral solution described in -4 according to claim 1, which is characterized in that the ingredient comprising following ratio:
。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710378798.7A CN108938562A (en) | 2017-05-25 | 2017-05-25 | Choline Glycerophosphate oral solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710378798.7A CN108938562A (en) | 2017-05-25 | 2017-05-25 | Choline Glycerophosphate oral solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108938562A true CN108938562A (en) | 2018-12-07 |
Family
ID=64494084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710378798.7A Pending CN108938562A (en) | 2017-05-25 | 2017-05-25 | Choline Glycerophosphate oral solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108938562A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072759A1 (en) * | 2004-01-16 | 2005-08-11 | Amerilab Technologies, Inc. | Effervescent composition including cranberry extract |
| CN103622981A (en) * | 2012-08-27 | 2014-03-12 | 康阳润和（北京）医药科技有限公司 | Compound glycyrrhizin oral liquid and preparation method thereof |
| KR20140094679A (en) * | 2013-01-14 | 2014-07-31 | 주식회사 바이오파마티스 | Controlled release pharmaceutical composition comprising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same |
| CN105920609A (en) * | 2016-06-08 | 2016-09-07 | 芜湖福民生物药业有限公司 | Choline alfoscerate-containing medicine and preparation method thereof |
-
2017
- 2017-05-25 CN CN201710378798.7A patent/CN108938562A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072759A1 (en) * | 2004-01-16 | 2005-08-11 | Amerilab Technologies, Inc. | Effervescent composition including cranberry extract |
| CN103622981A (en) * | 2012-08-27 | 2014-03-12 | 康阳润和（北京）医药科技有限公司 | Compound glycyrrhizin oral liquid and preparation method thereof |
| KR20140094679A (en) * | 2013-01-14 | 2014-07-31 | 주식회사 바이오파마티스 | Controlled release pharmaceutical composition comprising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same |
| CN105920609A (en) * | 2016-06-08 | 2016-09-07 | 芜湖福民生物药业有限公司 | Choline alfoscerate-containing medicine and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| RICCI, A等: "ORAL CHOLINE ALFOSCERATE COUNTERACTS AGE-DEPENDENT LOSS OF MOSSY FIBERS IN THE RAT HIPPOCAMPUS", 《MECHANISMS OF AGEING AND DEVELOPMENT》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maiga et al. | Antioxidant and 15-lipoxygenase inhibitory activities of the Malian medicinal plants Diospyros abyssinica (Hiern) F. White (Ebenaceae), Lannea velutina A. Rich (Anacardiaceae) and Crossopteryx febrifuga (Afzel) Benth.(Rubiaceae) | |
| Lee et al. | Clarification of the phenotypic characteristics and anti-tumor activity of Hedyotis diffusa | |
| US20130189382A1 (en) | Use of fucoxanthin in the preparation of product for improving memory and having neuroprotective effect associated with neurodegenerative disorder | |
| BR112013028776B1 (en) | Pterostilbene for use in relieving or preventing anxiety | |
| CN109939102B (en) | Pharmaceutical composition containing butylphthalide and borneol and application thereof | |
| Aderbauer et al. | In vitro and in vivo trypanocidal effect of lipophilic extracts of medicinal plants from Mali and Burkina Faso | |
| JP4975069B2 (en) | Tyrosinase inhibitor | |
| Zhang et al. | Protective effects of DJ-1 medicated Akt phosphorylation on mitochondrial function are promoted by Da-Bu-Yin-Wan in 1-methyl-4-phenylpyridinium-treated human neuroblastoma SH-SY5Y cells | |
| ES2394316T3 (en) | Pharmaceutical compositions of Carapa Guianensis. | |
| KR101851010B1 (en) | Compositions for the antiinflammatory and the antimicrobial activities | |
| CA2895429C (en) | Pharmaceutical compound for the prevention and treatment of a cognitive, neurodegenerative or neuronal disorder or disease | |
| KR101227758B1 (en) | Composition for improving atopic dermatitis comprising extract of Quercus variabilis which is extracted from wood chip of Quercus variabilis obtained by steam explosion treatment | |
| JP2023539925A (en) | Senenolytic compounds and compositions | |
| CN108938562A (en) | Choline Glycerophosphate oral solution | |
| TW201043609A (en) | Application of Acacia extracts and their phytocompounds on the inhibition of xanthine oxidase | |
| US11096906B2 (en) | Pharmaceutical composition for preventing or treating Alzheimer's disease | |
| US11173142B2 (en) | Cancer treatment composition | |
| US20060198914A1 (en) | Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders | |
| KR20130078992A (en) | The extract from dalbergia odorifera t. having skin whitening activity | |
| CN104510752A (en) | Medical application of astrapterocarpan | |
| CA2560267A1 (en) | Methods for increasing neurotransmitter levels using hydroxycitric acid | |
| CN114469934B (en) | Composition and pharmaceutical preparation thereof | |
| WO2012040919A1 (en) | Use of baicalein in manufacturing medicament for preventing and treating parkinson's disease | |
| CN117159626A (en) | Composition of caffeoylspermidine compound, use thereof and spermidine supplement thereof | |
| CN117304054A (en) | Enrichment method of caffeoylspermidine compound, anti-aging property and method for inhibiting histone deacetylase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181207 |
|
| WD01 | Invention patent application deemed withdrawn after publication |